- Previous Close
11.44 - Open
11.30 - Bid 11.02 x 100
- Ask 11.00 x 100
- Day's Range
10.73 - 11.30 - 52 Week Range
2.70 - 14.78 - Volume
19,838 - Avg. Volume
33,821 - Market Cap (intraday)
1.043B - Beta (5Y Monthly) 1.46
- PE Ratio (TTM)
-- - EPS (TTM)
-0.20 - Earnings Date Jan 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Feb 27, 2023
- 1y Target Est
--
BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.
www.bgm.ltd298
Full Time Employees
September 30
Fiscal Year Ends
Sector
Recent News: BGM
View MorePerformance Overview: BGM
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BGM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BGM
View MoreValuation Measures
Market Cap
1.04B
Enterprise Value
1.03B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.09
Price/Book (mrq)
24.41
Enterprise Value/Revenue
40.84
Enterprise Value/EBITDA
1.17k
Financial Highlights
Profitability and Income Statement
Profit Margin
-26.32%
Return on Assets (ttm)
-3.84%
Return on Equity (ttm)
-16.52%
Revenue (ttm)
29.87M
Net Income Avi to Common (ttm)
-7.86M
Diluted EPS (ttm)
-0.20
Balance Sheet and Cash Flow
Total Cash (mrq)
25.36M
Total Debt/Equity (mrq)
0.22%
Levered Free Cash Flow (ttm)
3.36M